

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Eucardic 25 mg Tablets

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 25 mg carvedilol.

### Excipients with known effect

Each tablet contains 10 mg lactose monohydrate and 25 mg sucrose.

For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Tablet

Round, white to pale beige tablets, scored on both sides, marked BM on one side and D5 on the other.

The tablet can be divided into equal doses.

## 4 CLINICAL PARTICULARS

### 4.1 Therapeutic indications

Adjunctive therapy for the treatment of symptomatic congestive heart failure to reduce morbidity and increase patient well-being.

Treatment of hypertension.

Long-term management of stable angina pectoris.

### 4.2 Posology and method of administration

#### Posology

#### **Symptomatic congestive heart failure**

The dosage must be titrated to individual requirements and monitored during up-titration.

For those patients receiving diuretics and/or digoxin and/or ACE inhibitors, dosing of these other medicinal products should be stabilised prior to initiation of Eucardic treatment.

#### *Adults*

The recommended dose for the initiation of therapy is 3.125 mg (half a 6.25 mg tablet) twice a day for two weeks. If this dose is tolerated, the dosage should be increased subsequently, at intervals of not less than two weeks, to 6.25 mg twice daily, followed by 12.5 mg twice daily and thereafter 25 mg twice daily. Dosing should be increased to the highest level tolerated by the patient.

The maximum recommended dose is 25 mg twice daily for all patients with severe CHF and for patients with mild to moderate CHF weighing less than 85 kg (187 lbs). In patients with mild or moderate CHF weighing more than 85 kg, the maximum recommended dose is 50 mg twice daily.

Before each dose increase the patient should be evaluated by the physician for symptoms of worsening heart failure or vasodilation. Transient worsening of heart failure, vasodilation or fluid retention may be treated with increased doses of

diuretics or ACE inhibitors or by modifying or temporarily discontinuing Eucardic treatment. Under these circumstances, the dose of Eucardic should not be increased until symptoms of worsening heart failure or vasodilation have been stabilised. If carvedilol treatment is discontinued for more than one week, therapy should be recommenced at a lower dose level (twice daily) and up-titrated in line with the above dosing recommendation. If Eucardic is discontinued for more than two weeks, therapy should be recommenced at 3.125 mg (half a 6.25 mg tablet) twice daily and up-titrated in line with the above dosing recommendation.

#### *Elderly*

As for adults.

### **Hypertension**

Once daily dosing is recommended.

#### *Adults*

The recommended dose for initiation of therapy is 12.5 mg once a day for the first two days. Thereafter the recommended dosage is 25 mg once a day. Although this is an adequate dose in most patients, if necessary the dose may be titrated up to a recommended daily maximum dose of 50 mg given once a day or in divided doses.

Dose titration should occur at intervals of at least two weeks.

#### *Elderly*

An initial dose of 12.5 mg daily is recommended. This has provided satisfactory control in some cases. If the response is inadequate the dose may be titrated up to the recommended daily maximum dose of 50 mg given once a day or in divided doses.

### **Angina**

#### *Adults*

The recommended dose for initiation of therapy is 12.5 mg twice a day for the first two days. Thereafter, the recommended dosage is 25 mg twice a day. If necessary, the dose may be titrated up to 50 mg twice a day.

Dose titration should occur at intervals of at least two weeks.

#### *Elderly*

The recommended maximum daily dose is 50 mg given in divided doses.

### **Special dosage instructions**

As with all beta-blockers, treatment should not be stopped abruptly but rather gradually reduced at weekly intervals. This is particularly important in the case of patients with concomitant coronary heart disease.

#### *Renal impairment*

Pharmacokinetic data and clinical studies in patients with renal impairment (including renal failure) suggest no dose adjustment is needed in moderate to severe renal impairment (see sections 4.4 and 5.2).

#### *Paediatric population*

The safety and efficacy of Eucardic in children and adolescents aged under 18 years has not been established (see section 5.1).

### **Method of administration**

Eucardic tablets are for oral use only. The tablets should be taken with fluid.

For Congestive Heart Failure (CHF) patients Eucardic should be given with food to slow the rate of absorption and reduce the incidence of orthostatic effects.

### **4.3 Contraindications**

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Unstable/decompensated heart failure requiring intravenous inotropic support
- Clinically manifest liver dysfunction

*As with other beta-blocking agents:*

- History of bronchospasm or asthma
- 2nd and 3rd degree atrioventricular (AV) heart block, (unless a permanent pacemaker is in place)
- Severe bradycardia (< 50 bpm)
- Cardiogenic shock
- Sick sinus syndrome (including sino-atrial block)
- Severe hypotension (systolic blood pressure < 85 mmHg).

#### **4.4 Special warnings and precautions for use**

*Chronic congestive heart failure:* In congestive heart failure patients, worsening cardiac failure or fluid retention may occur during up-titration of Eucardic. If such symptoms occur, diuretics should be increased and the Eucardic dose should not be further increased until clinical stability resumes. Occasionally it may be necessary to lower the Eucardic dose or, in rare cases, temporarily discontinue it. Such episodes do not preclude subsequent successful up-titration of Eucardic.

Eucardic should be used with caution in combination with digitalis glycosides, since both medicinal products slow AV conduction (see section 4.5).

*Renal function in congestive heart failure:* Reversible deterioration of renal function has been observed with Eucardic therapy in chronic heart failure patients with low blood pressure (systolic BP < 100 mmHg), ischaemic heart disease and diffuse vascular disease, and/or underlying renal insufficiency. In CHF patients with these risk factors, renal function should be monitored during up-titration of Eucardic and the medicinal product discontinued or dosage reduced if worsening of renal failure occurs.

*Chronic obstructive pulmonary disease:* Carvedilol should be used with caution in patients with chronic obstructive pulmonary disease (COPD) with a bronchospastic component who are not receiving oral or inhaled medication, and only if the potential benefit outweighs the potential risk. In patients with a tendency to bronchospasm, respiratory distress can occur as a result of a possible increase in airway resistance. Patients should be closely monitored during initiation and up-titration of carvedilol and the dose of Eucardic should be reduced if any evidence of bronchospasm is observed during treatment.

*Diabetes:* Care should be taken in the administration of Eucardic to patients with diabetes mellitus, as it may be associated with worsening control of blood glucose. Furthermore, the early signs and symptoms of acute hypoglycaemia may be masked or attenuated. Alternatives to beta-blocking agents are generally preferred in insulin-dependent patients. Therefore, regular monitoring of blood glucose is required in diabetics when Eucardic is initiated or up-titrated and hypoglycaemic therapy adjusted accordingly (see section 4.5).

*Peripheral vascular disease and Raynaud's phenomenon:* Eucardic should be used with caution in patients with peripheral vascular disease (e.g. Raynaud's phenomenon) as beta-blockers can precipitate or aggravate symptoms of arterial insufficiency.

*Thyrotoxicosis:* Eucardic may obscure the symptoms of thyrotoxicosis.

*Bradycardia:* Eucardic may induce bradycardia. If the patient's pulse rate decreases to less than 55 beats per minute, the dosage of Eucardic should be reduced.

*Hypersensitivity:* Care should be taken in administering Eucardic to patients with a history of serious hypersensitivity reactions and in patients undergoing desensitisation therapy as beta-blockers may increase both the sensitivity towards allergens and the severity of hypersensitivity reactions.

*Risk of Anaphylactic Reaction:* While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.

*Severe cutaneous adverse reactions (SCARs):* Very rare cases of severe cutaneous adverse reactions such as toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) have been reported during treatment with Eucardic (see section 4.8). Eucardic should be permanently discontinued in patients who experience severe cutaneous adverse reactions possibly attributable to Eucardic.

*Psoriasis:* Patients with a history of psoriasis associated with beta-blocker therapy should be given Eucardic only after consideration of the risk-benefit ratio.

*Interactions with other medicinal products:* There are a number of important pharmacokinetic and pharmacodynamic interactions with other medicinal products (e.g., digoxin, ciclosporin, rifampicin, anaesthetics, antiarrhythmics. See section 4.5).

*Phaeochromocytoma:* In patients with phaeochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent. Although Eucardic has both alpha- and beta-blocking pharmacological activities, there is no experience of the use of carvedilol in this condition. Therefore, caution should be taken in the administration of Eucardic to patients suspected of having phaeochromocytoma.

*Prinzmetal's variant angina:* Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal's variant angina. There is no clinical experience with carvedilol in these patients, although the alpha-blocking activity of Eucardic may prevent such symptoms. Caution should be taken in the administration of Eucardic to patients suspected of having Prinzmetal's variant angina.

*Contact lenses:* Wearers of contact lenses should be advised of the possibility of reduced lacrimation.

*Withdrawal syndrome:* Although angina has not been reported on stopping treatment, discontinuation should be gradual (over a period of 2 weeks), particularly in patients with ischaemic heart disease, as Eucardic has beta-blocking activity.

*Lactose:* This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

*Sucrose:* This medicinal product contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

## **4.5 Interaction with other medicinal products and other forms of interaction**

### **Pharmacokinetic interactions:**

#### *Effects of Eucardic on the pharmacokinetics of other medicinal products*

Carvedilol is a substrate as well as an inhibitor of P-glycoprotein. Therefore, the bioavailability of drugs transported by P-glycoprotein may be increased with concomitant administration of carvedilol. In addition, the bioavailability of carvedilol can be modified by inducers or inhibitors of P-glycoprotein.

*Digoxin:* An increased exposure of digoxin of up to 20% has been shown in some studies in healthy subjects and patients with heart failure. A significantly larger effect has been seen in male patients compared to female patients. Therefore, monitoring of digoxin levels is recommended when initiating, adjusting or discontinuing carvedilol (see section 4.4). Carvedilol had no effect on digoxin administered intravenously.

*Ciclosporin and tacrolimus:* Two studies in renal and cardiac transplant patients receiving oral ciclosporin have shown an increase in ciclosporin plasma concentration following the initiation of carvedilol. It appears that carvedilol increases exposure to oral ciclosporin by around 10 to 20%. In an attempt to maintain therapeutic ciclosporin levels, an average 10 to 20% reduction of the ciclosporin dose was necessary. The mechanism for the interaction is not known but inhibition of intestinal P-glycoprotein by carvedilol may be involved. Due to wide interindividual variability of ciclosporin levels, it is recommended that ciclosporin concentrations are monitored closely after initiation of carvedilol therapy and that the dose of ciclosporin be adjusted as appropriate. In case of intravenous administration of ciclosporin, no interaction with carvedilol is expected. Furthermore, there is evidence that CYP3A4 is involved in the metabolism of carvedilol. As tacrolimus is a substrate of P-glycoprotein and CYP3A4, its pharmacokinetics may also be affected by carvedilol through these interaction mechanisms.

*Effects of other medicinal products and substances on the pharmacokinetics of Carvedilol*

Inhibitors as well as inducers of CYP2D6 and CYP2C9 can modify the systemic and/or presystemic metabolism of carvedilol stereoselectively, leading to increased or decreased plasma concentrations of *R*- and *S*-carvedilol (see section 5.2). Some examples observed in patients or in healthy subjects are listed below but the list is not exhaustive.

*Rifampicin*: In a study in 12 healthy subjects, exposure to carvedilol decreased by around 60% during concomitant administration with rifampicin and a decreased effect of carvedilol on the systolic blood pressure was observed. The mechanism for the interaction is not known but it may be due to the induction of the intestinal P-glycoprotein by rifampicin. A close monitoring of the beta-blockade activity in patients receiving concomitant administration of carvedilol and rifampicin is appropriate.

*Amiodarone*: An *in vitro* study with human liver microsomes has shown that amiodarone and desethylamiodarone inhibited the oxidation of *R*- and *S*-carvedilol. The trough concentration of *R*- and *S*-carvedilol was significantly increased by 2.2-fold in heart failure patients receiving carvedilol and amiodarone concomitantly as compared to patients receiving carvedilol monotherapy. The effect on *S*-carvedilol was attributed to desethylamiodarone, a metabolite of amiodarone, which is a strong inhibitor of CYP2C9. A monitoring of the beta-blockade activity in patients treated with the combination carvedilol and amiodarone is advised.

*Fluoxetine and paroxetine*: In a randomized, cross-over study in 10 patients with heart failure, coadministration of fluoxetine, a strong inhibitor of CYP2D6, resulted in stereoselective inhibition of carvedilol metabolism with a 77% increase in mean *R*-enantiomer's AUC, and a non-significant 35% increase of the *S*-enantiomer's AUC as compared to the placebo group. However, no differences in adverse events, blood pressure or heart rate were noted between treatment groups. The effect of single dose paroxetine, a strong CYP2D6 inhibitor, on carvedilol pharmacokinetics was investigated in 12 healthy subjects following single oral administration. Despite significant increase in *R*- and *S*-carvedilol exposure, no clinical effects were observed in these healthy subjects.

*Alcohol*: Alcohol intake is shown to have acute hypotensive effects which may augment the blood pressure reduction caused by carvedilol. As carvedilol is soluble in ethanol, the presence of alcohol could affect the rate and/or extent of intestinal absorption of carvedilol. Also, carvedilol is partly metabolized by CYP2E1, an enzyme known to be induced and inhibited by alcohol.

*Grapefruit juice*: Consumption of a single dose of 300 ml grapefruit juice results in a 1.2-fold increase of the AUC of carvedilol in comparison to water. While clinical relevance is unclear, patients should avoid concomitant intake of grapefruit juice, at least until a stable dose-response relationship is established.

**Pharmacodynamic interactions:**

*Insulin or oral hypoglycaemics*: Agents with beta-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycaemics. The signs of hypoglycaemia may be masked or attenuated (especially tachycardia). In patients taking insulin or oral hypoglycaemics, regular monitoring of blood glucose is therefore recommended (see section 4.4).

*Catecholamine-depleting agents*: Patients taking both agents with beta-blocking properties and a medicinal product that can deplete catecholamines (e.g. reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.

*Digoxin*: The combined use of beta-blockers and digoxin may result in additive prolongation of atrioventricular (AV) conduction time.

*Non-dihydropyridine calcium channel blockers, amiodarone or other antiarrhythmics*: The combined use of non-dihydropyridine calcium channel blockers, amiodarone or other antiarrhythmics with carvedilol can increase the risk of AV conduction disturbances (see section 4.4). Isolated cases of conduction disturbance (rarely with haemodynamic compromise) have been observed when carvedilol is co-administered with diltiazem. As with other agents with beta-blocking properties, if carvedilol is to be administered orally with non-dihydropyridinecalcium channel blockers of the verapamil or diltiazem type, amiodarone or other antiarrhythmics it is recommended that ECG and blood pressure be monitored.

*Clonidine*: Concomitant administration of clonidine with agents with beta-blocking properties may potentiate blood pressure and heart rate lowering effects. When concomitant treatment with agents with beta-blocking properties and clonidine is to be terminated, the beta-blocking agent should be discontinued first. Clonidine therapy can then be discontinued several days later by gradually decreasing the dosage.

*Antihypertensives*: As with other agents with beta-blocking activity, Eucardic may potentiate the effect of other concomitantly administered medicinal products that are anti-hypertensive in action (e.g. alpha<sub>1</sub>-receptor antagonists) or have hypotension as part of their adverse effect profile.

*Anaesthetic agents*: Careful attention must be paid during general anaesthesia to the synergistic negative inotropic and hypotensive effects of carvedilol and anaesthetics (see section 4.4).

*Non-steroidal anti-inflammatory drugs (NSAIDs)*: The concurrent use of non-steroidal anti-inflammatory drugs (NSAIDs) and beta-adrenergic blockers may result in an increase in blood pressure and impairment of blood pressure control.

*Beta-agonist bronchodilators*: Non-cardioselective beta-blockers oppose the bronchodilator effects of beta-agonist bronchodilators. Careful monitoring of patients is recommended.

## **4.6 Fertility, pregnancy and lactation**

### Pregnancy

There is no adequate clinical experience with carvedilol in pregnant women.

Animal studies demonstrated effects on pregnancy, embryonal/foetal development, parturition, reproductive toxicity and postnatal development (see section 5.3). The potential risk for humans is unknown.

Carvedilol should not be used during pregnancy unless the potential benefit outweighs the potential risk.

Beta-blockers reduce placental perfusion which may result in intrauterine foetal death and immature and premature deliveries. In addition, adverse effects (especially hypoglycaemia and bradycardia) may occur in the foetus and neonate. There may be an increased risk of cardiac and pulmonary complications in the neonate in the postnatal period. Animal studies have not shown substantive evidence of teratogenicity with carvedilol (see also section 5.3).

### Breastfeeding

Animal studies demonstrated that carvedilol and/or its metabolites are excreted in rat breast milk. The excretion of carvedilol in human milk has not been established. However, most beta-blockers, in particular lipophilic compounds, will pass into human breast milk although to a variable extent. Breastfeeding is therefore not recommended following administration of carvedilol.

## **4.7 Effects on ability to drive and use machines**

No studies of the effects on ability to drive and use machines have been performed.

As for other medicinal products which produce changes in blood pressure, patients taking carvedilol should be warned not to drive or operate machinery if they experience dizziness or related symptoms. This applies particularly when starting, dose increasing or changing treatment and in conjunction with alcohol.

## **4.8 Undesirable effects**

### *(a) Summary of the safety profile*

The frequency of adverse reactions is not dose-dependent except for dizziness, visual disturbances and bradycardia.

### *(b) Table of adverse reactions*

The risk of most adverse reactions associated with carvedilol is similar for all indications. The exceptions are described in subsection (c).

The following undesirable effects have been reported (e.g. from clinical trials, post-authorisation safety studies or spontaneous reporting) to occur when carvedilol is administered:

Frequency categories are as follows:

Very common  $\geq 1/10$

Common  $\geq 1/100$  to  $< 1/10$

Uncommon  $\geq 1/1,000$  to  $< 1/100$

Rare  $\geq 1/10,000$  to  $< 1/1,000$

Very rare  $< 1/10,000$

**Table 1: Adverse Reactions**

System Organ Class	Adverse Reaction	Frequency
Infections and infestations	Pneumonia	Common
	Bronchitis	Common
	Upper respiratory tract infection	Common
	Urinary tract infection	Common
Blood and lymphatic system disorders	Anaemia	Common
	Thrombocytopenia	Rare
	Leukopenia	Very rare
Immune system disorders	Hypersensitivity (allergic reactions)	Very rare
Metabolism and nutrition disorders	Weight increase	Common
	Hypercholesterolaemia	Common
	Impaired blood glucose control (hyperglycaemia, hypoglycaemia) in patients with pre-existing diabetes	Common
Psychiatric disorders	Depression, depressed mood	Common
	Sleep disorders	Uncommon
Nervous system disorders	Dizziness	Very common
	Headache	Very Common
	Syncope, presyncope	Common
	Paraesthesia	Uncommon
Eye disorders	Visual impairment	Common
	Lacrimation decreased (dry eye)	Common
	Eye irritation	Common
Cardiac disorders	Cardiac failure	Very common
	Bradycardia	Common
	Hypervolaemia (fluid overload)	Common
	Atrioventricular block	Uncommon
	Angina pectoris	Uncommon
Vascular disorders	Hypotension	Very common
	Orthostatic hypotension	Common
	Disturbances of peripheral circulation (cold extremities, peripheral vascular disease, exacerbation of intermittent claudication and Raynaud's phenomenon)	Common
	Hypertension	Common
Respiratory, thoracic and mediastinal disorders	Dyspnoea	Common
	Pulmonary oedema	Common
	Asthma in predisposed patients	Common
	Nasal congestion, flu-like symptoms	Rare
Gastrointestinal disorders	Nausea	Common
	Diarrhoea	Common
	Vomiting	Common
	Dyspepsia	Common
	Abdominal pain	Common
	Constipation	Uncommon

	Dry mouth	Rare
Hepatobiliary disorders	Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT) increased	Very rare
Skin and Subcutaneous disorders	Skin reactions (e.g. allergic exanthema, dermatitis, urticaria, pruritus, psoriatic and lichen planus like skin lesions), alopecia	Uncommon
Musculoskeletal and connective tissue disorders	Pain in extremities	Common
Renal and urinary disorders	Renal failure and renal function abnormalities in patients with diffuse vascular disease and/or underlying renal insufficiency	Common
	Micturition disorders	Rare
	Urinary incontinence in women	Very rare
Reproductive system and breast disorders	Erectile dysfunction	Uncommon
General disorders and administration site conditions	Asthenia (fatigue)	Very common
	Oedema	Common
	Pain	Common

#### *Description of selected adverse reactions*

The frequency of adverse reactions is not dose-dependent, with the exception of dizziness, abnormal vision and bradycardia. Dizziness, syncope, headache and asthenia are usually mild and are more likely to occur at the beginning of treatment.

In congestive heart failure patients, worsening cardiac failure and fluid retention may occur during up-titration of carvedilol dose (see section 4.4).

Cardiac failure was a very commonly reported adverse event in both placebo (14.5%) and carvedilol-treated (15.4%) patients, in patients with left ventricular dysfunction following acute myocardial infarction.

Reversible deterioration of renal function has been observed with carvedilol therapy in chronic heart failure patients with low blood pressure, ischaemic heart disease and diffuse vascular disease and/or underlying renal insufficiency (see section 4.4).

The following adverse events have been identified during post-marketing use of carvedilol. Because these events are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency and/or establish a causal relationship to medicinal product exposure:

#### *Metabolism and nutrition disorders*

As a class, beta-adrenergic receptor blockers may cause latent diabetes to become manifest, manifest diabetes to be aggravated, and blood glucose counter-regulation to be inhibited.

#### *Psychiatric disorders*

Carvedilol may cause hallucinations.

#### *Cardiac disorders*

Sinus arrest may occur in predisposed patients (e.g. elderly patients or patients with pre-existing bradycardia, sinus node dysfunction or atrioventricular block).

#### *Skin and subcutaneous tissue disorders*

Severe cutaneous adverse reactions (Toxic epidermal necrolysis, Stevens-Johnson syndrome (see section 4.4)).  
Hyperhidrosis.

#### *Renal and urinary disorders*

Carvedilol may cause urinary incontinence in women which resolves upon discontinuation of the medication.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the HPRA Pharmacovigilance Website: [www.hpra.ie](http://www.hpra.ie)

## 4.9 Overdose

### *Symptoms and signs:*

In the event of overdose, there may be severe hypotension, bradycardia, heart failure, cardiogenic shock, sinus arrest and cardiac arrest. There may also be respiratory problems, bronchospasm, vomiting, disturbed consciousness and generalised seizures.

### *Treatment:*

The patients should be monitored for the above-mentioned signs and symptoms and managed according to the best judgment of the treating physicians and according to standard practice for patients with beta-blocker overdose (e.g. atropine, transvenous pacing, glucagon, phosphodiesterase inhibitor such as amrinone or milrinone, beta-sympathomimetics).

Gastric lavage or induced emesis may be useful in the first few hours after ingestion.

In cases of severe overdose with symptoms of shock, supportive treatment as described should be continued for a sufficiently long period of time, i.e. until the patient stabilises, since prolonged elimination half-life and redistribution of carvedilol from deeper compartments can be expected.

## 5 PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Alpha- and beta-blocking agents. ATC code: C07AG02.

#### Mechanism of action

Carvedilol, a racemic mixture of two enantiomers (*R*- and *S*-carvedilol), is a multiple action alpha- and beta-adrenergic receptor blocker. The beta-adrenergic receptor blockade is associated with the *S*-enantiomer and non-selective for beta<sub>1</sub>- and beta<sub>2</sub>-adrenoceptors, while both enantiomers have the same blocking properties specific for alpha<sub>1</sub>-adrenoceptors. At higher concentrations, carvedilol also has a weak to moderate calcium-channel blocking activity. It has no intrinsic sympathomimetic activity and (like propranolol) it has membrane-stabilising properties.

#### Pharmacodynamic effects

Carvedilol reduces peripheral vascular resistance by selective blockade of alpha<sub>1</sub>-adrenoceptors. Through its beta-blocking action, carvedilol suppresses the renin-angiotensin-aldosterone system, reducing the release of renin and making fluid retention rare. It attenuates the increase in blood pressure induced by phenylephrine, an alpha<sub>1</sub>-adrenoceptor agonist, but not that induced by angiotensin II. Carvedilol's calcium-channel blocking activity may increase blood flow in specific vascular beds such as the cutaneous circulation.

Carvedilol has organ-protective effects, likely resulting at least in part from additional properties beyond its adrenergic receptor blockade action. It has potent antioxidant properties associated with both enantiomers, is a scavenger of reactive oxygen radicals and has antiproliferative effects on human vascular smooth muscle cells.

Carvedilol has no adverse effect on the lipid profile.

#### Clinical efficacy and safety

Clinical studies have shown that the balance of vasodilation and beta-blockade provided by carvedilol results in the following effects:

#### *Hypertension*

Carvedilol lowers blood pressure in hypertensive patients by beta-blockade and alpha<sub>1</sub>-mediated vasodilation, without a concomitant increase in total peripheral resistance, as observed with pure beta-blocking agents. Heart rate is slightly decreased. Renal blood flow and renal function are maintained. Carvedilol has been shown to maintain stroke volume and reduce total

peripheral resistance, without compromising blood supply to distinct organs and vascular beds, e.g. kidneys, skeletal muscles, forearms, legs, skin, brain or the carotid artery. There is a reduced incidence of cold extremities and early fatigue during physical activity.

#### *Hypertensive patients with renal impairment*

Several open studies have shown that carvedilol is effective in patients with renal hypertension, chronic renal failure, on haemodialysis or after renal transplantation. Carvedilol causes a gradual reduction in blood pressure on dialysis and non-dialysis days, and blood pressure-lowering effects are comparable with those seen in patients with normal renal function.

#### *Stable Angina pectoris*

In patients with stable angina, Eucardic has demonstrated anti-ischaemic (improved total exercise time, time to 1 mm ST segment depression and time to angina) and anti-anginal properties that were maintained during long-term treatment. Acute haemodynamic studies demonstrated that carvedilol significantly decreases myocardial oxygen demand and sympathetic over-activity, and reduces both cardiac pre-load (pulmonary artery pressure and pulmonary capillary wedge pressure) and after-load (total peripheral resistance) with consequent improvement in left ventricular systolic and diastolic function without substantial changes in the cardiac output.

Eucardic has no adverse effects on the metabolic risk factors of coronary heart disease. It does not impair the normal serum lipid profile and in hypertensive patients with dyslipidaemia favourable effects on the serum lipids have been reported after six months of oral therapy.

In two studies, Eucardic 25 mg b.i.d. was compared with other anti-anginal medicinal products of recognised value in patients with chronic stable exertional angina. The dose regimens that were chosen were those widely used in clinical practice. Both trials had a double-blind, parallel group design. The primary objective was total exercise time (TET).

Report no:	Control (dose)	Patient numbers carvedilol/comparator drug	Duration of treatment
060	Verapamil (120 mg t.i.d.)	126/122	12 weeks
061	ISDN s.r. (40 mg b.i.d.)	93/94	12 weeks

The results of both trials clearly demonstrated that for TET at trough blood drug levels after 12 weeks of therapy there was no statistically significant difference between treatment groups. However, the risk ratios obtained from the Cox proportional hazards model showed a trend in favour of carvedilol indicating that on average carvedilol was 114% as effective as verapamil (90% CI: 85-152%) and 134% as effective as ISDN (90% CI: 96-185%). This was also true for time to angina (TTA) and ST-segment depression (TST) at trough. The increase in TET was about 50 seconds in all groups; the improvements for TTA and TST were about 30 seconds, which is clinically relevant.

In study 060, 48h Holter monitoring data measurements demonstrated a reduction of number and duration of ST-segment depressions (silent myocardial ischaemia) in both treatment groups. Carvedilol also decreased premature atrial and ventricular contractions (PAC, PVC), couplets and runs.

#### *Chronic Heart Failure*

Carvedilol significantly reduces mortality and hospitalisations and improves symptoms and left ventricular function in patients with ischaemic or non-ischaemic chronic heart failure. The effect of carvedilol is dose dependent.

#### *Chronic Heart Failure patients with renal impairment*

Carvedilol reduces morbidity and mortality in dialysis patients with dilated cardiomyopathy, as well as all-cause mortality, cardiovascular mortality and heart failure mortality or first hospitalization in heart failure patients with mild to moderate non-dialysis-dependent chronic kidney disease. A meta-analysis of placebo-controlled clinical trials including a large number of patients (> 4,000) with mild to moderate chronic kidney disease supports carvedilol treatment of patients with left ventricular dysfunction with or without symptomatic heart failure to reduce rates of all cause of mortality as well as heart failure related events.

#### *Paediatric population*

The safety and efficacy of carvedilol in children and adolescents has not been established due to limited number and size of studies. Available studies focus on treatment of paediatric heart failure which differs from the disease in adults regarding characteristics and aetiology. Because of the small number of participants compared to studies in adults and a general lack of an optimal dosing scheme for children and adolescents, the available data is not sufficient to establish a paediatric safety profile for carvedilol.

## 5.2 Pharmacokinetic properties

### Absorption

Following oral administration of a 25 mg capsule to healthy subjects, carvedilol is rapidly absorbed with a peak plasma concentration  $C_{max}$  of 21 µg/L reached after approximately 1.5 hour ( $t_{max}$ ). The  $C_{max}$  values are linearly related to the dose. Following oral administration, carvedilol undergoes extensive first pass metabolism that results in an absolute bioavailability of about 25% in healthy male subjects. Carvedilol is a racemate and the *S*-enantiomer appears to be metabolized more rapidly than the *R*-enantiomer, showing an absolute oral bioavailability of 15% compared to 31% for the *R*-enantiomer. The maximal plasma concentration of *R*-carvedilol is approximately 2-fold higher than that of *S*-carvedilol.

*In vitro* studies have shown that carvedilol is a substrate of the efflux transporter P-glycoprotein. The role of P-glycoprotein in the disposition of carvedilol was also confirmed *in vivo* in healthy subjects.

Food does not affect bioavailability, residence time or the maximum serum concentration although the time to reach maximum serum concentration is delayed.

### Distribution

Carvedilol is highly lipophilic, showing a plasma protein binding of around 95%. The distribution volume ranges between 1.5 and 2 L/kg and increased in patients with liver cirrhosis.

### Biotransformation

In humans, carvedilol is extensively metabolized in the liver via oxidation and conjugation into a variety of metabolites that are eliminated mainly in the bile. Enterohepatic circulation of the parent substance has been shown in animals.

Demethylation and hydroxylation at the phenol ring produce three metabolites with beta-adrenergic receptor blocking activity. Based on pre-clinical studies, the 4'-hydroxy-phenol metabolite is approximately 13 times more potent than carvedilol for beta-blockade. Compared to carvedilol, the three active metabolites exhibit weak vasodilating activity. In humans, the concentrations of the three active metabolites are about 10 times lower than that of the parent substance. Two of the hydroxy-carbazole metabolites of carvedilol are extremely potent antioxidants, demonstrating a 30 to 80-fold greater potency than carvedilol.

Pharmacokinetic studies in humans have shown that the oxidative metabolism of carvedilol is stereoselective. The results of an *in vitro* study suggested that different cytochrome P450 isoenzymes may be involved in the oxidation and hydroxylation processes including CYP2D6, CYP3A4, CYP2E1, CYP2C9, as well as CYP1A2.

Studies in healthy volunteers and in patients have shown that the *R*-enantiomer is predominantly metabolized by CYP2D6. The *S*-enantiomer is mainly metabolized by CYP2D6 and CYP2C9.

### *Genetic polymorphism*

The results of clinical pharmacokinetic studies in human subjects have shown that CYP2D6 plays a major role in the metabolism of *R*- and of *S*-carvedilol. As a consequence, plasma concentrations of *R*- and *S*-carvedilol are increased in CYP2D6 slow metabolisers. The importance of CYP2D6 genotype in the pharmacokinetics of *R*- and *S*-carvedilol was confirmed in population pharmacokinetics studies, whereas other studies did not confirm this observation. It was concluded that CYP2D6 genetic polymorphism may be of limited clinical significance.

### Elimination

Following a single oral administration of 50 mg carvedilol, around 60% is secreted into the bile and eliminated with the faeces in the form of metabolites within 11 days. Following a single oral dose, only about 16% is excreted into the urine in form of carvedilol or its metabolites. The urinary excretion of unaltered drug represents less than 2%. After intravenous infusion of 12.5 mg to healthy volunteers, the plasma clearance of carvedilol reaches around 600 mL/min and the elimination half-life around 2.5 hours. The elimination half-life of a 50 mg capsule observed in the same individuals was 6.5 hours corresponding indeed to the absorption half-life from the capsule. Following oral administration, the total body clearance of the *S*-carvedilol is approximately two times larger than that of the *R*-carvedilol.

### **Special populations**

*Elderly:* Age has no statistically significant effect on the pharmacokinetics of carvedilol in hypertensive patients.

*Paediatric population:* The weight-adjusted clearance in children and adolescents is significantly larger than in adults.

*Hepatic impairment:* In a study in patients with cirrhotic liver disease, the bioavailability of carvedilol was four times greater and the peak plasma level five times higher than in healthy subjects.

*Renal impairment:* Since carvedilol is primarily excreted via the faeces, significant accumulation in patients with renal impairment is unlikely. In patients with hypertension and renal insufficiency, the area under plasma level-time curve, elimination half-life and maximum plasma concentration does not change significantly. Renal excretion of the unchanged drug decreases in the patients with renal insufficiency; however changes in pharmacokinetic parameters are modest. Carvedilol is not eliminated during dialysis because it does not cross the dialysis membrane, probably due to its high plasma protein binding.

*Heart failure:* In a study in 24 Japanese patients with heart failure, the clearance of *R*- and *S*-carvedilol was significantly lower than previously estimated in healthy volunteers. These results suggested that the pharmacokinetics of *R*- and *S*-carvedilol is significantly altered by heart failure in Japanese patients.

### 5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential.

#### Impairment of fertility

Administration of carvedilol to adult female rats at toxic doses ( $\geq 200$  mg/kg,  $\geq 100$  times MRHD) resulted in impairment of fertility (poor mating, fewer corpora lutea and fewer implants).

#### Teratogenicity

There is no evidence from animal studies that carvedilol has any teratogenic effects.

#### Embryotoxicity

Embryotoxicity was observed only after large doses in rabbits. Doses  $> 60$  mg/kg ( $> 30$  times MRHD) caused delays in physical growth/development of offspring. There was embryotoxicity (increased post-implantation deaths) but no malformations in rats and rabbits at doses of 200 mg/kg and 75 mg/kg, respectively (38 to 100 times MRHD). The relevance of these findings for humans is uncertain. In addition, animal studies have shown that carvedilol crosses the placental barrier and therefore the possible consequences of alpha- and beta-blockade in the human foetus and neonate should also be borne in mind (also see section 4.6).

In summary, effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use (see section 4.6)

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Lactose monohydrate  
Sucrose  
Povidone (E 1201)  
Crospovidone (E 1202)  
Colloidal anhydrous silica (E 551)  
Magnesium stearate (E 572)

### 6.2 Incompatibilities

Not applicable.

### 6.3 Shelf life

5 years.

### 6.4 Special precautions for storage

11 October 2023

CRN00DGXN

Page 12 of 13

This medicinal product does not require any special temperature storage conditions.  
Store in the original package in order to protect from moisture and light.

#### **6.5 Nature and contents of container**

Oriented Polyamide/Aluminium/PVC blister

Blisters are packed in cartons containing 14, 28, 30 or 100 tablets.

Not all pack sizes may be marketed.

#### **6.6 Special precautions for disposal**

No special requirements.

### **7 MARKETING AUTHORISATION HOLDER**

Cheplapharm Arzneimittel GmbH  
Ziegelhof 24  
17489  
Greifswald  
Germany

### **8 MARKETING AUTHORISATION NUMBER**

PA2239/001/003

### **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 19<sup>th</sup> January 1995

Date of last renewal: 3<sup>rd</sup> April 2008

### **10 DATE OF REVISION OF THE TEXT**

October 2023